APP Seminar Series

UNIVERSITY OF SASKATCHEWAN
College of Medicine
DEPARTMENT OF ANATOMY, PHYSIOLOGY AND PHARMACOLOGY
MEDICINE.USASK.CA

12:30 pm on Thursday, April 4, 2024

Location: E1130 HLTH

Zoom Link: https://usask-ca.zoom.us/j/91662933615?pwd=NzE0ZVk2Y1RKY2ZPV0N4YVkzc1pMdz09

Controlling Inflammation in Cystic Fibrosis: Keys to Success

Dr. Larry Lands, PhD

Professor, Department of Pediatrics
Associate Member of the Department of Medicine, Division of Experimental Medicine



Cystic Fibrosis (CF) is an autosomal recessive disease caused by mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). Inflammation is a critical factor in CF lung disease progression, with a vicious cycle of inflammation and infection leading to lung damage, respiratory failure, and premature death. Despite advances in therapies with CFTR modulators, there is persistent ongoing inflammation. Understanding how dysfunctional CFTR stimulates respiratory epithelial cell inflammation can guide potential therapeutic approaches.

Dr. Larry Lands, MD, PhD is a tenured full professor of Pediatrics at McGill University and Director of the Division of Pediatric Respiratory Medicine and the Pediatric Cystic Fibrosis Clinic at the McGill University Health Centre-Montreal Children's Hospital. He is Chair of CF Canada's Research Advisory Council and co-Chair of the protocol review committee of CF Canada's clinical research network, CFCanACT. His fundamental research investigates respiratory epithelial inflammation and therapeutics. He is currently developing inhalable lipid nanoparticles for delivery of therapeutic small molecules and nucleic acids.